Migraine Without Aura Clinical Trial
Official title:
IndoProCaf (Difmetre®) Effervescent Tablets Effectiveness in Acute Treatment of Primary Headaches (Migraine and/or Episodic Tension-type Headache) and Patients' Satisfaction With the Treatment in Routine Clinical Practice in Ukraine and Kazakhstan
Headaches are a common medical problem that physicians frequently encounter in their practice. One of key findings of The Atlas of Headache Disorders prepared by World Health Organization (WHO) is: headache disorders, including migraine and tension-type headache (TTH), are among the most prevalent disorders of mankind. The fixed combination of indomethacin, prochlorperazine and caffeine (IndoProCaf) showed efficacy and safety in acute treatment of migraine and episodic tension-type headache attacks. IndoProCaf (Difmetre®) is widely used in common daily practice only in Italy from early 1970s, is available at the Commonwealth of Independent States (CIS) pharmaceutical market now. There are limited data regarding IndoProCaf usage from post-marketing settings. This will be a first post-marketing observational study which aimed to evaluate the effectiveness and patients' satisfaction of primary headaches acute treatment in routine clinical settings in Ukraine and Kazakhstan.
The study is designed as a prospective, multicentre, observational, non-interventional, non-randomized, non-controlled, single arm, post-marketing study where IndoProCaf will be prescribed in the usual manner per standard clinical practice of the treating physician and in accordance with the terms of the locally approved instruction for medical use. No additional procedures (other than the standard of care) shall be applied to the patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
Completed |
NCT01687660 -
Acupuncture for Migraine Prophylaxis
|
N/A | |
Completed |
NCT00363532 -
Functional MRI (fMRI) in CGRP Induced Migraine
|
N/A | |
Completed |
NCT00123201 -
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
|
Phase 2 | |
Completed |
NCT04406649 -
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
|
Phase 3 | |
Completed |
NCT03874832 -
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05565001 -
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.
|
N/A | |
Completed |
NCT04533568 -
Ibuprofen in Migraine Patients
|
Phase 4 | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Recruiting |
NCT05416476 -
Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
|
Phase 3 | |
Completed |
NCT04636359 -
Study the Effect of Acupuncture on Migraine Patient Without Aura Via Functional Magnetic Resonance Imaging.
|
N/A | |
Completed |
NCT00534560 -
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
|
Phase 2 | |
Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
Completed |
NCT00380263 -
PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow
|
N/A | |
Completed |
NCT00334178 -
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
|
Phase 3 | |
Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
Recruiting |
NCT06414044 -
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
|
||
Completed |
NCT03472378 -
Can DFN-15 Terminate Migraine With Allodynia?
|
Phase 2 | |
Recruiting |
NCT05211154 -
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
|
Phase 4 |